321 related articles for article (PubMed ID: 35911723)
21. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
23. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
24. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
[TBL] [Abstract][Full Text] [Related]
25. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
[TBL] [Abstract][Full Text] [Related]
27. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
29. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
30. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
Yin GQ; Li ZL; Li D
Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
[TBL] [Abstract][Full Text] [Related]
31. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
32. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
34. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
35. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
36. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
Li C; Yu P; Li H; Yang X; Wang J; Jiang B
J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
[TBL] [Abstract][Full Text] [Related]
37. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
[No Abstract] [Full Text] [Related]
39. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
40. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
